KEGG enrichment analysis revealed an enrichment of the NAFLD pathway, suggesting that SLXG may potentially treat nonalcoholic steatohepatitis (NASH) by regulating the expression of genes such as CXCL8, AKT1, SREBF1, IL6, PPARA, and ADIPOQ (Fig. 3B). Here, AKT1 is linked to metabolic dysfunction-associated steatotic liver disease.